Vertex executives warned that Casgevy, its curative treatment for sickle cell disease, would be slow to reach patients. But ...

A new way to escalate privileges inside Google’s Vertex AI highlights a broader problem: Enterprises have a level of trust in AI offerings that needs to be fundamentally reexamined. The finding of ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $438.92, moving -2.36% from the previous trading session. This change lagged the S&P 500's daily gain of 0.26%. Elsewhere, the Dow ...

Vertex Inc. (NASDAQ:VERX) is one of the best beaten down stocks to invest in according to analysts. On December 5, Vertex Inc. (NASDAQ:VERX) confirmed expansion of its strategic partnership with ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

This strengthens Google’s position against rivals such as Microsoft and AWS as enterprises seek faster, more reliable ways to deploy and manage AI agents. Google Cloud has updated its Vertex AI Agent ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

If your Word equation is not converting to professional format, you’re not alone. Some users have reported that equations typed in Microsoft Word on a Windows 11/10 PC fail to switch from linear text ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice ...

Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multitarget drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.